相关实验视频
Updated: May 1, 2026

16:15
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
20.6K
基因组和生物标志物创新预测移植拒绝
Rachana Punukollu1, Sandesh Parajuli2, Harshad Chaudhari1
1Division of Nephrology, Mayo Clinic, Phoenix, AZ 85054, USA.
Journal of clinical medicine
|June 13, 2025
概括
非侵入性生物标志物,如来自捐赠者的无细胞DNA (dd-cfDNA) 和基因表达特征 (GEP) 显示出检测移植排斥的潜力,为移植监测提供了侵入性活检的替代方案.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 移植免疫学 移植免疫学
- 生物标志物发现发现
背景情况:
- 移植等待名单很长,许多患者由于移植失败需要重新移植.
- 异种移植的排斥是造成移植失败的主要原因.
- 组织活检是目前拒绝诊断的标准,是侵入性的,不适合持续监测.
研究的目的:
- 审查用于检测和预测移植拒绝的非侵入性生物标志物.
- 突出非侵入性排斥监测方面的进展.
- 专注于排除组织活检的方法.
主要方法:
- 对移植排斥的非侵入性生物标志物研究的文献综述.
- 专注于来自供体的无细胞DNA (dd-cfDNA) 和基因表达造型 (GEP).
- 包括新兴的生物标志物,如扭矩延伸病毒 (TTV).
主要成果:
- 为识别急性排斥,突出显示了来自捐赠者的无细胞DNA (dd-cfDNA) 和基因表达概况 (GEP).
- 扭矩病毒 (TTV) 显示出作为免疫抑制和排斥风险的间接标记物的潜力.
- 该审查强调非侵入性方法,不包括依赖活检的研究.
结论:
- 非侵入性生物标志物为移植排斥监测提供了侵入性活检的可行替代方案.
- dd-cfDNA,GEP和TTV代表了非侵入性排斥检测进步的关键领域.
- 对这些生物标志物的进一步研究可以改善长期的移植存活率和患者的结果.
相关概念视频
What is Genetic Engineering?
70.6K
Overview
70.6K
In-vitro Mutagenesis
14.8K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.8K
Plant Breeding and Biotechnology
17.2K
Crop cultivation has a long history in human civilization, with records showing the cultivation of cereal plants beginning at around 8000 BC. This early plant breeding was developed primarily to provide a steady supply of food.
17.2K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121

